IP Library Granted Patent US 10,775,386
Granted Patent B2
US 10,775,386 · App. 15/702,719 · Granted Sep 15, 2020

Methods of detecting anti-leptin neutralizing antibodies

Inventor: Jeffrey Sailstad (Durham, NC)
Assignee: Aegerion Pharmaceuticals, Inc.
G01N33/6854G01N33/74G01N2333/575G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,775,386
App. No.
15/702,719
Granted
Sep 15, 2020
Kind
B2
Abstract

Provided herein are methods for detecting neutralizing antibodies to leptins, including metreleptin, as well as identifying subjects having such neutralizing antibodies.

Claims (43)

1. A method of detecting neutralizing antibodies to leptin in a test sample obtained from a human subject, wherein the test sample is a blood, serum, or plasma sample, the method comprising the steps of:

(a) inactivating leptin present in the test sample;

(b) adding a known quantity of labeled leptin to the test sample;

(c) contacting the sample containing labeled leptin of (b) with a substrate capable of binding the labeled leptin;

(d) washing the substrate to remove unbound labeled leptin;

(e) measuring the label signal produced by the substrate-bound labeled leptin;

(f) measuring a negative control signal, said negative control signal produced by completing steps (a)-(e) in a control blood, serum, or plasma sample that does not contain antileptin neutralizing antibodies; and

(g) comparing the signal from (e) with the signal from (f), wherein if the level of signal measured in (e) is greater than or equal to the level of signal measured in (f), then the sample does not contain neutralizing antibodies to leptin, and wherein if the level of signal measured in (e) is less than the level of signal measured in (f), then the sample contains neutralizing antibodies to leptin.

2. A method of identifying human subjects having neutralizing antibodies to leptin in blood, serum, or plasma from the subject comprising the steps of:

(a) inactivating leptin present in the sample of blood, serum, or plasma;

(b) adding a known quantity of labeled leptin to the sample;

(c) contacting the sample containing labeled leptin of (b) with a substrate capable of binding the labeled leptin;

(d) washing the substrate to remove unbound labeled leptin;

(e) measuring the label signal produced by the bound labeled leptin;

(f) measuring a negative control signal, said negative control signal produced by completing steps (a)-(e), wherein the sample of blood, serum, or plasma does not contain antileptin neutralizing antibodies; and

(g) comparing percent difference in the signal from (e) and the signal from (f) with a cutpoint, wherein if the percent difference in the signal from (e) and the signal from (f) is greater than the cutpoint, then the subject tests positive for anti-leptin neutralizing antibodies.

3. The method of claim 2 , wherein the cutpoint is between about 5% and about 40%.

4. The method of claim 3 , wherein the subject is a healthy subject, and the cutpoint is between about 7% and about 8%.

5. The method of claim 1 , wherein the leptin is labeled with horseradish peroxidase, or ruthenium tris-bipyridine.

6. The method of claim 1 , wherein the inactivation step (a) is accomplished by heating the sample.

7. The method of claim 1 , wherein said substrate capable of binding the labeled leptin comprises:

i. a coated matrix;

ii. a tagged leptin receptor bound to the matrix of (i).

8. The method of claim 7 , wherein the leptin receptor is tagged with biotin.

9. The method of claim 1 , wherein said substrate capable of binding the labeled leptin comprises:

i. a coated matrix;

ii. an antibody bound to the matrix of (i); and

iii. a tagged leptin receptor bound to the antibody of (ii).

10. The method of claim 9 , wherein the leptin receptor is tagged with a tag suitable for affinity purification.

11. The method of claim 9 , wherein the antibody has suitable affinity for the leptin receptor tag.

12. The method of claim 9 , where the antibody is labeled with a tag suitable to bind to the coated matrix.

13. The method of claim 2 , wherein the inactivation step (a) is accomplished by heating the sample.

14. The method of claim 2 , wherein said substrate capable of binding the labeled leptin comprises:

i. a coated matrix;

ii. a tagged leptin receptor bound to the matrix of (i).

15. The method of claim 14 , wherein the leptin receptor is tagged with biotin.

16. The method of claim 2 , wherein said substrate capable of binding the labeled leptin comprises:

i. a coated matrix;

ii. an antibody bound to the matrix of (i); and

iii. a tagged leptin receptor bound to the antibody of (ii).

17. The method of claim 16 , wherein the leptin receptor is tagged with a tag suitable for affinity purification.

18. The method of claim 16 , wherein the antibody has suitable affinity for the leptin receptor tag.

19. The method of claim 16 , where the antibody is labeled with a tag suitable to bind to the coated matrix.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2023
From: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: AMRYT PHARMACEUTICALS, INC.; AMRYT ENDO, INC.; AMRYT RESEARCH LIMITED; AMRYT GENETICS LIMITED
Reel/Frame 063318/0849 →
RELEASE OF SECURITY INTEREST Recorded Feb 23, 2022
From: CANTOR FITZGERALD SECURITIES, AS ADMINISTRATIVE AGENT
To: AEGERION PHARMACEUTICALS, INC.; AMRYT RESEARCH LIMITED
Reel/Frame 059074/0604 →
SECURITY INTEREST Recorded Feb 18, 2022
From: AMRYT PHARMACEUTICALS, INC.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 059049/0164 →
CHANGE OF NAME Recorded May 10, 2021
From: AEGERION PHARMACEUTICALS, INC.
To: AMRYT PHARMACEUTICALS, INC.
Reel/Frame 056193/0437 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2020
From: SAILSTAD, JEFFREY
To: AEGERION PHARMACEUTICALS, INC.
Reel/Frame 052590/0679 →
SECURITY INTEREST Recorded Sep 24, 2019
From: AEGERION PHARMACEUTICALS, INC.
To: CANTOR FITZGERALD SECURITIES, AS ADMINISTRATIVE AGENT
Reel/Frame 050478/0204 →
RELEASE OF SECURITY INTEREST Recorded Sep 24, 2019
From: CANTOR FITZGERALD SECURITIES, AS ADMINISTRATIVE AGENT
To: AEGERION PHARMACEUTICALS, INC.
Reel/Frame 050478/0629 →
RELEASE OF SECURITY INTEREST Recorded Sep 24, 2019
From: NOVELION THERAPEUTICS INC.
To: AEGERION PHARMACEUTICALS, INC.
Reel/Frame 050478/0695 →
SECURITY INTEREST Recorded Nov 8, 2018
From: AEGERION PHARMACEUTICALS, INC.
To: CANTOR FITZGERALD SECURITIES, AS ADMINISTRATIVE AGENT
Reel/Frame 047447/0926 →
PATENT SECURITY AGREEMENT Recorded Nov 8, 2018
From: AEGERION PHARMACEUTICALS, INC.
To: NOVELION THERAPEUTICS INC.
Reel/Frame 047455/0385 →
Continuity (2)
Provisional Application 62393632 · Sep 12, 2016
Related Publication 20180074073A1 · Mar 15, 2018